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The majority of men diagnosed with prostate cancer have 
high 10-year survival rates due to improved screening, 
detection, and treatments (Wong et al., 2016). Unfortunately, 
these men have heightened risk for depression related to 
unmet psychosocial needs, prostate cancer–related symp-
toms, and treatment side effects that can include sexual 
dysfunction and urinary incontinence (Chambers et al., 
2017). Many men with prostate cancer can suffer from 
additional health problems (i.e., sexual dysfunction and 
heart disease) that may contribute to depressive symptoms 
(D’Amico, Chen, Renshaw, Loffredo, & Kantoff, 2008; 
Saini et al., 2013). Depression among men with prostate 
cancer has emerged as a significant issue with prevalence 
reported at 16% to 30% (Christie & Sharpley, 2014; Sharp, 
O’Leary, Kinnear, Gavin, & Drummond, 2016; Sharpley, 
Bitsika, & Christie, 2010, 2013; Sharpley & Christie, 
2007). Depression in prostate cancer is associated with 
men experiencing a loss of masculine identity (Sharpley, 
Bitsika, & Denham, 2014). Severe depression is a known 
risk for suicide, especially among older prostate cancer 
patients (Llorente et al., 2005). Although awareness of 
depression in prostate cancer has grown, the wider men’s 
health literature suggests depression among men is under-
diagnosed (Oliffe & Phillips, 2008). Research attention has 
thus been increasingly devoted to the specificities of men’s 
depressive symptoms, the contexts in which they are expe-
rienced, and the methods and tools used to formally evalu-
ate depression in men.
The generic diagnostic criteria for major depressive 
disorder, as per the Diagnostic and Statistical Manual 
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Abstract
Depression in men with prostate cancer is a significant and complex issue that can challenge clinicians’ diagnostic 
efforts. The objective of the current study was to evaluate prototypic and male-specific depression symptoms and 
suicidal ideation in men with a diagnosis of prostate cancer relative to those with and without comorbidity. The Patient 
Health Questionnaire-9 (PHQ-9) and Male Depression Risk Scale-22 (MDRS-22) were completed online along with 
demographic and background variables by 100 men with a diagnosis of prostate cancer (n = 54 prostatectomy, n = 
33 receiving active treatment). Hierarchical logistic regression was used to examine recent (past 2 weeks) suicide 
ideation. Over one-third of the sample (38%) reported a comorbidity, and this group had significantly higher total 
depression scores on the PHQ-9 (Cohen’s d = 0.65), MDRS-22 emotion suppression (d = 0.35), and drug use subscales 
(d = 0.38) compared to respondents without comorbidity. A total of 14% reported recent suicidal ideation, of which 
71.4% of cases were identified by the PHQ-9 “moderate” cut-off, and 85.7% of cases were identified by the MDRS-
22 “elevated” cut-off. After control variables, MDRS-22 subscales accounted for 45.1% of variance in recent suicidal 
ideation. While limited by the exclusive use of self-report data, findings point to the potential benefits of evaluating 
male-specific symptoms as part of depression and suicide risk screening in men with prostate cancer and the need to 
be mindful of the heightened risk for depression among men with prostate cancer who have comorbidity.
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(DSM-5), have been critiqued as gender neutral and 
insufficient to comprehensively evaluate depression in 
men (Sharpley, Bitsika, & Christie, 2014). At a broad 
level, such critiques have produced a focus on highlight-
ing male-specific depressive symptoms and the design 
and testing of tools to more accurately diagnose and treat 
men’s depression. Systematic reviews and population 
studies support these efforts by arguing for the existence 
of a subtype of depression in men characterized by alco-
hol/substance use and externalizing symptoms including 
anger and irritability (Cavanagh, Wilson, Kavanagh, & 
Caputi, 2017; Martin, Neighbors, & Griffith, 2013). 
Expansion of the assessment of depression may be par-
ticularly important for men with prostate cancer. For 
example, Sharp et al. (2016) argued that psychological 
evaluation of men with prostate cancer should be 
informed by better understanding their cancer-related 
symptoms, rather than focusing on the major depressive 
disorder criteria. This was based on findings that men 
who experience prostate cancer–related urinary inconti-
nence and those treated with androgen deprivation ther-
apy, who in turn experienced fatigue and insomnia, were 
more likely to be depressed (Sharp et al., 2016). 
Unpleasant emotions and social withdrawal from others 
were also highlighted as significant factors associated 
with depression severity in a sample of 800 prostate can-
cer patients (Sharpley et al., 2010).
Nonetheless, depression scales that emphasize inter-
nalizing symptoms in the diagnosis of major depressive 
disorder continue to be used widely in prostate cancer 
patients. For example, the Patient Health Questionnaire-9 
(PHQ-9) performed reliably in testing several aspects of 
depression in cancer patients (Hinz et al., 2016); how-
ever, according to Sharpley et al. (Sharpley, Bitsika, & 
Christie, 2014), the PHQ-9 does not fully capture the 
dimensions of depression as they manifest in men with 
prostate cancer. Specifically, the PHQ-9 and the Gotland 
Male Depression Scale (GMDS) were compared for 
their capacity to measure the prevalence of depression in 
191 men with prostate cancer, and approximately 24% of 
the men screened as depressed on the GMDS were not 
identified by the PHQ-9 (Sharpley, Bitsika, & Christie, 
2014). The GMDS has, however, drawn criticisms 
regarding psychometric validity, highlighting the need 
for measurement refinement amid the emergence of 
other male depression scales (Rice, Aucote, Möller-
Leimkühler, & Amminger, 2017). Among the newer 
scales, the Male Depression Risk Scale-22 (MDRS-22) 
has shown much promise and has been validated in gen-
eral populations of Canadian and Australian men to iden-
tify males at risk of depression (Rice et al., 2017; Rice, 
Oliffe, Kealy, & Ogrodniczuk, 2018). The scale assesses 
six broad externalizing domains of depression symptoms 
in men, including emotion suppression and anger and 
aggression, and may offer improved detection and early 
intervention among males at risk for depression and sui-
cidal ideation.
The objective of the current study was to evaluate and 
compare PHQ-9 and MDRS-22 self-report data among 
men with prostate cancer relative to those with and with-
out comorbidities (e.g., cardiovascular problems, arthri-
tis, and chronic pain). The second aim was to evaluate the 
predictive ability of the MDRS-22 in identifying recent 
suicidal ideation in this population. Given evidence sug-
gesting that men with prostate cancer who experience 
comorbidity report greater psychosocial stress and poorer 
outcomes (D’Amico et al., 2008; Saini et al., 2013), it 
was predicted that higher scores for prototypic and male-
specific depression symptoms would be observed among 
men reporting comorbidity.
Methods
Participants
This study used a convenience sample of 100 Canadian 
men with prostate cancer, recruited online and via social 
media. Men self-identified as having prostate cancer and 
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indicating year of diagnosis and providing information 
regarding current treatment and symptoms.
Measures
Demographic information included country and province 
of residence, age, employment status, education level, 
sexual identity, cultural affiliation, year diagnosed with 
prostate cancer and year treated, prostate cancer 
treatment[s], and current treatment. Data for comorbidity 
were collected using an item labeled “Other health chal-
lenges” to which respondents could indicate “yes” [Please 
specify] or “no.” The PHQ-9 (Kroenke, Spitzer, & 
Williams, 2001), developed from the diagnostic criteria 
for major depressive disorder, comprises nine items 
reflecting the diagnostic criteria in the DSM-V (American 
Psychological Association [APA], 2013). Respondents 
indicated how often (0 = “not at all,” 1 = “several days,” 
2 = “more than half the days,” and 3 = “nearly every 
day”) they had been bothered by any of the listed 
problems over the last 2 weeks (see Table 1 for items). 
The PHQ-9 has excellent validity for individuals with 
mild, moderate, and severe depression (Kroenke et al., 
2001), with aggregate scores ranging from 0 to 27 that 
map minimal depression (0–4), mild depression (5–9), 
moderate depression (10–14), moderately severe depres-
sion (15–19), and severe depression (20–27). The MDRS-
22 comprises 22 items and six subscales focused on 
externalizing depression symptoms (Rice, Fallon, Aucote, 
& Möller-Leimkühler, 2013). Respondents, thinking 
back over the last month, responded to each item consid-
ering how often (0 = not at all to 7 = almost always) spe-
cific statements applied to them (see Table 2 for MDRS-22 
subscales). The MDRS-22 exhibits test–retest stability 
and excellent psychometric properties (Rice et al., 2015) 
and has been validated in Australian and Canadian sam-
ples with the total score characterizing those in the low 
(0–31), elevated (32–50), high (51–86), and extreme 
ranges (87–154; Rice et al., 2017).
Procedure
Following approval from the behavioral ethics review 
board at (University of British Columbia), the survey was 
Table 1. Group Comparison for PHQ-9 Items.
Total sample, 
N = 100
No comorbidity, 
n = 62
Comorbidity, 
n = 38 Group comparison
PHQ-9 itema M (SD) M (SD) M (SD) F p Cohen’s d
Little interest or pleasure in 
doing things
0.72 (0.95) 0.60 (0.91) 0.92 (1.00) 2.48 .099 0.33
Feeling down, depressed, or 
hopeless
0.68 (0.82) 0.52 (0.74) 0.94 (0.87) 7.00 .010 0.52
Trouble falling asleep or sleeping 
too much
1.00 (1.03) 0.79 (0.91) 1.34 (1.15) 7.11 .009 0.53
Feeling tired or having little 
energy
1.14 (1.09) 0.81 (0.97) 1.68 (1.07) 17.81 <.001 0.85
Poor appetite or overeating 0.62 (0.87) 0.50 (0.82) 0.82 (0.92) 3.15 .079 0.36
Feeling bad about yourself or 
that you are a failure or have 
let yourself or family down
0.56 (0.70) 0.47 (0.67) 0.71 (0.73) 2.88 .093 0.34
Trouble concentrating on things, 
such as reading the newspaper 
or watching television
0.63 (0.87) 0.48 (.80) 0.86 (0.93) 4.75 .032 0.34
Moving or speaking so slowly 
that other people could have 
noticed. Or the opposite being 
so fidgety or restless that you 
have been moving around a lot 
more than usual
0.30 (0.58) 0.19 (.44) 0.47 (0.72) 5.81 .018 0.47
Thoughts that you would be 
better off dead or of hurting 
yourself in some way
0.20 (0.55) 0.16 (.45) 0.26 (0.55) 0.81 .372 0.20
Note. aPHQ-9 item scores range 0–3. PHQ-9 = Patient Health Questionnaire-9; SD = standard deviation.
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embedded in an online prostate cancer psychosocial 
resource. The website and survey were launched in 
January 2017, highlighting the issue of depression in men 
with prostate cancer, and the opportunity for respondents 
to be entered into a $500 cash prize draw by completing 
the survey. The survey was available for 3 months to 
April 2017, and recruitment was aided by targeted 
Facebook ads and social media posts inviting men with 
prostate cancer to respond by clicking on the hyper-
linked survey. The survey landing page provided details 
about the study including consent, confidentiality 
regards respondent’s demographic data, and its separate 
password protected storage from their survey responses, 
along with details about the aggregated data being 
shared as study findings in an academic publication and 
presentations. On completion of the survey, respondents 
were provided the URL of a men’s depression website 
(https://headsupguys.org/), which provided visitors with 
male-specific depression information and supports.
Data Analysis
Analyses were undertaken in SPSS 22.0 (IBM Corp.). 
Descriptive statistics were used to characterize the sam-
ple based on self-reported sexuality, cultural affiliation, 
and highest education. Independent sample t tests were 
used to compare groups (i.e., those with and without self-
reported comorbidity) on age, and χ2 analyses were used 
to evaluate the associations between treatment groups 
(i.e., current active treatment and watchful waiting), 
recent diagnosis (i.e., last 12 months), and highest educa-
tion level. Reliability for the PHQ-9 and MDRS-22 sub-
scales was calculated using Cronbach’s α coefficients. 
Multivariate analysis of covariance was conducted on the 
PHQ-9 items and MDRS-22 subscales, controlling for cur-
rent treatment and age. χ2 analysis evaluated established 
PHQ-9 categories (i.e., normal PHQ-9 = 0–4, minimal 
PHQ-9 = 5–9, mild PHQ-9 = 10–14, and moderate–
severe PHQ-9 = 15–27) according to those with and with-
out comorbidities. Hierarchical logistic regression was 
undertaken to predict recent (past 2 weeks) suicide ide-
ation, as assessed by PHQ-9 item nine, controlling for 
age, recent diagnosis, current treatment, and sexuality 
(step 1) and comorbidity (step 2), with MDRS-22 sub-
scales entered at step 3.
Results
Sample Characteristics
Mean age of the sample was 64.8 (standard deviation 
[SD] = 7.18) years, ranging 47 to 85. The vast majority of 
the sample identified as heterosexual (n=96), and four 
participants identified as gay, bisexual, or preferred not to 
say. Most (n = 87) participants identified as Caucasian. 
More than 60% of the sample reported higher education: 
some college/trade school (n = 19); graduation from col-
lege/trade school (n = 23); some university (n = 7); under-
graduate degree (n = 17); and graduate degree (n = 21). 
Of the 38 participants indicating a comorbidity in addi-
tion to their prostate cancer diagnosis, only one reported 
a diagnosis of depression. A total of 11 participants 
reported multimorbidities. The remaining cases reported 
challenges with cardiovascular health (n = 10), arthritis 
(n = 7), chronic pain (n = 2), or other (n = 8; gallstones, 
diabetes). Recent suicidal ideation was relatively infre-
quent in the present sample (n = 14). One-third (n = 33) 
of the sample were receiving active treatment, and just 
over half (n=54) reported a prostatectomy.
There was no significant age difference between those 
without comorbidity (M = 64.55 years, SD = 7.07) and 
those reporting comorbidity (M = 65.24 years, SD = 7.42), 
p = .644. There was no association between those 
reporting comorbidity and current active treatment (n = 33, 
Table 2. Group Comparison for MDRS-22 Subscales.
Total sample, 
N = 100
No comorbidity, 
n = 62
Comorbidity, 
n=38 Group comparison
MDRS-22 Subscalea M (SD) M (SD) M (SD) F p Cohen’s d
Emotion suppression 8.73 (7.73) 7.58 (6.96) 10.61 (8.61) 4.56 .035 0.38
Drug use 1.03 (3.24) 0.50 (1.87) 1.89 (4.58) 4.77 .031 0.38
Alcohol use 2.51 (4.97) 2.71 (5.35) 2.18 (4.32) 0.20 .656 0.11
Anger and aggression 3.53 (5.18) 2.91 (4.37) 4.53 (6.22) 2.71 .103 0.30
Somatic symptoms 5.14 (5.35) 4.56 (5.38) 6.08 (5.25) 1.22 .140 0.28
Risk-taking 1.30 (2.61) 1.37 (2.44) 1.18 (2.88) 0.04 .843 0.07
Note. aMDRS-22 subscales range 0–28 for emotion suppression, alcohol use, anger and aggression, and somatic symptoms; MDRS-22 subscales 
range 0–21 for the drug use and risk-taking subscales. MDRS = Male Depression Risk Scale-22; SD = standard deviation.
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χ2(1) = 0.40, p = .522), watchful waiting (n = 22, 
χ2(1) = 1.72, p = .189), recent diagnosis of prostate can-
cer (i.e., last 12 months; n = 35, χ2(1) = 0.16, p = .690), 
highest education level (χ2(6) = 8.56, p = .200), or recent 
suicidal ideation (n = 6, χ2(1) = 0.16, p = .686).
Scale Reliability
The PHQ-9 demonstrated satisfactory internal consis-
tency (Cronbach’s α = .89). For the MDRS-22, all sub-
scales reported satisfactory internal consistency: emotion 
suppression (α =.88), drug use (α =.91), alcohol use 
(α =.91), anger and aggression (α =.92), somatic symp-
toms (α =.67), though internal consistency was low for 
the risk-taking subscale (α =.59). A subsequent sensitiv-
ity analysis of the risk-taking subscale, however, identi-
fied that the risk-taking subscale was internally consistent 
for those <65 years (n = 46, α =.70) relative to males ≥65 
years (n = 54, α =.07).
Comparison of Symptom Profiles
For the PHQ-9 total score, those with comorbidity 
reported significantly higher depression scores (M = 8.02, 
SD = 5.56) compared to those without comorbidity 
(M = 4.52, SD = 5.19), F(1, 96) = 10.87, p = .001, Cohen’s 
d = 0.65. Neither current treatment (p = .738) or age 
(p = .097) was significant covariates. When the nine 
PHQ-9 symptoms were examined in a multivariate 
analysis, a significant omnibus effect was observed, Λ = 
0.811, F(9, 90) = 2.33, p = .021, partial η2 = .189. Current 
treatment (p = .832) and age (p = .789) were not signifi-
cant covariates. Significant univariate effects were 
observed for five major depression symptoms; higher 
scores were observed for those with comorbidity for low 
mood, sleep disturbance, fatigue, concentration difficulty, 
and psychomotor disturbance (see Table 1).
Categorical analysis was undertaken according to 
PHQ-9 depression categories. A significant association 
indicated that those with comorbidity were less likely to 
be in the normal range and more likely to be in the mild 
and moderate symptom ranges than those with no 
comorbidity χ2(3, N = 100) = 8.024, p = .046. The same 
association held for the MDRS-22 χ2(3, N = 100) = 8.30, 
p = .040 (see Figure 1).
For the MDRS-22 total score, there was a nonsignifi-
cant trend for those with comorbidity to report higher 
scores (M = 26.47, SD = 21.24) compared to those without 
comorbidity (M = 19.65, SD = 17.64), F(1, 96) = 3.92, 
p = .051, Cohen’s d = 0.35, with neither current treatment 
(p = .931) or age (p = .097) significant as covariates. When 
the MDRS-22 subscales were examined in a multivariate 
analysis, a significant multivariate effect was observed, 
Λ=.863, F(6, 91) = 2.41, p = .033, partial η2 = .132, with 
neither current treatment (p = .992) or age (p = .058) sig-
nificant covariates. At the univariate level, there was a 
significant effect for the emotion suppression subscale, 
Figure 1. PHQ-9 and MDRS-22 categories (percentage with comorbidity).
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F(1, 96) = 4.56, p = .035, and the drug use subscale, 
F(1, 96) = 4.77, p = .031. In both instances, scores were 
higher among men with comorbidities.
Suicidal Ideation
Of the 14 respondents who endorsed suicidal ideation, the 
PHQ-9 cut-off score for “moderate depression” identified 
71.4% (n = 10) of those men, while the MDRS-22 “ele-
vated” cut-off identified 85.7% (n = 12). Bivariate corre-
lations were calculated between PHQ-9 total scores and 
the MDRS-22 subscales. Significant correlations were 
observed for five of the MDRS-22 subscales; emotion 
suppression (r = .66, p < .001), drug use (r = .22, p = 
.025), anger and aggression (r = .59, p < .001), somatic 
symptoms (r = .46, p < .001), and risk-taking (r=.41, p < 
.001). The logistic regression model was not significant 
with the control variables entered at either step 1 (χ2(4) = 
3.51, p =.447) or step 2 (χ2(5) = 3.77, p = .609) but was 
significant when the six MDRS-22 subscales were simul-
taneously entered at step 3 (χ2(11) = 33.75, p < .001). The 
model explained 51.8% of variance in recent suicide ide-
ation, with the MDRS-22 subscales accounting for 45.1% 
of variance (Nagelkerke R2). Increasing MDRS-22 emo-
tion suppression subscale scores were a significant pre-
dictor (Wald = 5.78, odds ratio [OR] = 1.18, p = .016), 
with a trend observed for the anger and aggression sub-
scale (Wald = 3.80, OR = 1.19, p = .051).
Discussion
There was a consistent pattern of higher scores for major 
depression symptoms for those men with prostate cancer 
reporting comorbidities (i.e., cardiovascular disease and 
arthritis), with a robust moderate effect size for the group 
difference in PHQ-9 total scores. Those reporting comor-
bidities were more likely to be in the mild or moderate–
severe range on the PHQ-9 than those without other 
health challenges. Specific effects were noted for low 
mood, sleep disturbance, fatigue, concentration difficulty, 
and psychomotor disturbance. This suggests that the like-
lihood of depression may increase in men experiencing 
prostate cancer who have comorbidities. These results 
indicate that it is not only the likelihood of depression 
severity that increases but also that the expression of 
depressive symptoms may be different for men with pros-
tate cancer who also report comorbidity. Given that many 
men with prostate cancer are in their sixth, seventh, and 
eighth decades, this is an important consideration in rou-
tinely evaluating depression levels in men with prostate 
cancer. It is likely that many of these men were treated 
with polypharmacy agents, some of which in and of 
themselves might heighten their risk for depression 
(Higano, 2003). There was no significant difference 
between those with and without comorbidities with 
regards to the suicidal ideation item on the PHQ-9. While 
this may reflect an equivalent degree of suicidal ideation 
between the two groups, there may also be benefit in 
more fully evaluating suicidality in men with prostate 
cancer beyond the single PHQ-9 item, “Thoughts that you 
would be better off dead, or of hurting yourself in some 
way.”
Patterns for the MDRS-22 were less consistent. Those 
reporting additional health challenges had significantly 
higher scores for the emotion suppression and drug use 
subscales. The drug use effect might be explained by 
respondents with comorbidity being reliant on polyphar-
macy agents for a range of conditions. In this regard, the 
MDRS-22 likely yields diverse interpretations of the drug 
use items wherein some respondents may use illicit drugs 
recreationally, responding on that basis, while others such 
as the current sample might be responding based on their 
prescription drug use. Nonetheless, since men with 
comorbidity were markedly more distressed (based on 
PHQ-9 scores) than those without comorbidity, this dif-
ference remains cause for some concern—perhaps sug-
gesting the overuse of drugs for emotional coping and/or 
for management of a higher pain burden. The effect for 
emotion suppression, which demonstrated the strongest 
correlation with the PHQ-9, suggests that those with 
comorbidity may attempt to self-censor and withhold the 
expression of negative emotion. Such responses may 
actually increase the likelihood of developing additional 
physical and mental health problems (Hoyt, Stanton, 
Irwin, & Thomas, 2013; Mauss & Gross, 2004). 
Furthermore, the current study findings indicate that the 
MDRS-22 risk-taking subscale may be less reliable in 
older men (i.e., those ≥65 years). This may be somewhat 
expected and likely reflects older men’s more conserva-
tive practices.
Beyond differences in symptom expression between 
men with and without comorbidities, unique associations 
were reported between overall depressive severity and two 
male-specific domains of the MDRS-22. Based on the 
regression analyses, anger and aggression also appeared to 
be salient among men with prostate cancer and comorbid-
ity, while emotion suppression appeared to be an important 
factor associated with prototypic symptoms of depression 
in men with prostate cancer in general. As older men, 
respondents may have aligned to traditional masculine ide-
als around stoicism and relied on anger and aggression to 
express their emotions, which in turn can manifest as mal-
adaptive coping. Experiencing prostate cancer and comor-
bidity may further threaten one’s sense of self as a man, 
evoking unmodulated anger (in protest and/or in compen-
sation) for their compromised health. Results from the 
regression analyses indicated that the MDRS-22 subscales 
accounted for a large proportion of variance in the PHQ-9 
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scores, approximately 48% for those without comorbidity 
and 53% of variance for those with comorbidities. The cur-
rent study findings suggest evaluation of emotion suppres-
sion in men with prostate cancer, along with anger and 
aggression in men with prostate cancer and comorbidity as 
important avenues of future research. That emotion sup-
pression was identified to be a significant predictor of sui-
cide ideation with a trend also observed for anger and 
aggression, suggests that additional research attention is 
paid to more fully apprehend and address these potential 
connections.
Clinical Implications
The current study findings have implications for 
researchers and care providers. Both groups should be 
aware of comorbidities in men with prostate cancer as 
depression risk factors, given this appears to be associ-
ated with higher PHQ-9 scores in the current sample. 
Supporting this recommendation, depression also 
appears to be underdiagnosed in this population. For 
example, among those reporting comorbidity, only one 
participant self-reported a diagnosis of depression. 
Figure 1 shows that there were 13 cases (i.e., 34%) in the 
comorbidity subgroup achieving the PHQ-9 cut-off score 
for either mild or moderate–severe depression. The 
observation that 22 of the 100 respondents’ PHQ-9 
scores also indicated mild to moderate–severe depres-
sion supports estimates of prevalence in the literature 
(Christie & Sharpley, 2014; Sharp et al., 2016; Sharpley 
et al., 2010, 2013; Sharpley & Christie, 2007). 
Furthermore, given their association with PHQ-9 scores, 
emotion suppression and anger and aggression in men 
should be taken into account by clinicians working with 
men who experience prostate cancer. This finding sup-
ports work by Sharpley and Bitsika (2014) and others 
(Oliffe & Phillips, 2008; Rice et al., 2013) indicating that 
a range of male-specific symptoms exist beyond those 
identified by generic depression screening tools, and that 
nuanced differences in the expression of such symptoms 
may emerge in the context of prostate cancer and comor-
bid conditions.
A proportion of men with prostate cancer will also 
experience suicidal ideation. Emotion suppression was 
found to be predictive of suicidal ideation in the present 
sample. When assessing for depression in this population, 
sensitive clinical enquiry regarding suicidal thoughts is 
suggested, along with assessing the likelihood of emotion 
suppression, given the potential association between 
these two constructs. Taking a wider view, adopting brief 
general screening tools such as the Distress Thermometer, 
a single-item measure validated in populations of men 
experiencing prostate cancer (Chambers, Zajdlewicz, 
Youlden, Holland, & Dunn, 2014), may also assist as a 
way to introduce clinical conversations about suicidal 
thinking.
In terms of prevention and treatment of depressive 
symptoms, Sharpley, Bitsika, Wootten, and Christie (2014) 
advocated for peer supports as an effective way to 
increase men’s resilience for coping with prostate cancer 
and alleviating depressive symptoms. A systematic 
review of randomized controlled trials drawn from pro-
grams to improve the psychological well-being of men 
with prostate cancer highlighted 11 effective interven-
tions (Chambers et al., 2017). These included online psy-
choeducation and moderated peer forums; however, 
these interventions and their evaluations were not based 
on translational knowledge about masculinity and male-
specific symptoms of depression (Chambers et al., 2017). 
Cormie et al. (2016) asserted the need to appeal to men’s 
masculine values through group-based physical exercise 
interventions. Such approaches may to promote social 
connectedness and reduce depression among men with 
prostate cancer (Cormie, Galvão, et al., 2015; Cormie, 
Turner, Kaczmarek, Drake, & Chambers, 2015). Building 
on these insights and recommendations by Sharpley 
et al. (2017), future work might also focus on prevention 
and treatments of depression among specific subgroups, 
with formal evaluation of prostate cancer psychosocial 
programs inclusive of end-users’ depressive symptoms 
and scores over time.
More broadly, findings have implications for the 
field of men’s depression research. In the present sam-
ple, the MDRS-22 cut-off identified additional cases of 
suicidality that fell below the PHQ-9 cut-off. As sug-
gested by others (Rice, Kealy, Oliffe, & Ogrodniczuk, 
2018), case identification may be improved by supple-
menting the use of standard depression symptom rating 
scales with male-specific measures. Furthermore, emo-
tion suppression predicted suicidality in the present 
sample. This accords with recent population-based epi-
demiological work indicating that men’s stoicism is a 
robust predictor of suicidal ideation (Pirkis, Spittal, 
Keogh, Mousaferiadis, & Currier, 2017). Ongoing atten-
tion to men’s use of emotion suppression and tendency 
for stoicism is indicated.
Study Limitations
The current study has several limitations: the use of 
nonprobability sampling precludes generalizability of 
ﬁndings; the cross-sectional design prohibits causal 
inference; the exclusive use of self-report measures 
including the lack of follow-up screening and diagnosis 
by a clinician; and the small sample size. Furthermore, 
suicidal ideation was assessed by a single item from the 
PHQ-9; however, research has previously supported use 
of this item (Walker et al., 2010). Future studies should 
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use large samples and longitudinal designs to fully 
examine the role of age, comorbidities, and treatment 
modalities in men’s depression across the prostate can-
cer trajectory.
Summary
To address depression in men with prostate cancer, more 
effective screening for depressive symptoms is needed, 
and future interventions should be designed and formally 
evaluated on understandings of relative depression risk 
and specific symptomatology in men with prostate can-
cer. By highlighting the increased risk for depression in 
men with prostate cancer who have comorbidity, and the 
predictive nature of emotion suppression and anger and 
aggression on PHQ-9 scores, the current study reveals 
the need for asking additional clinical and research ques-
tions of this subgroup of men who are vulnerable to 
depression.
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